title: Lymphoproliferative disease after intestinal transplantation under primary FK 506 immunosuppression.
authors.affiliation: Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh Transplant Institute, Pennsylvania.
authors.forename: J
authors.initials: J
authors.lastname: Reyes
authors.forename: A G
authors.initials: AG
authors.lastname: Tzakis
authors.forename: H
authors.initials: H
authors.lastname: Bonet
authors.forename: M
authors.initials: M
authors.lastname: Green
authors.forename: E
authors.initials: E
authors.lastname: Yunis
authors.forename: M
authors.initials: M
authors.lastname: Nalesnik
authors.forename: B
authors.initials: B
authors.lastname: Nour
authors.forename: S
authors.initials: S
authors.lastname: Kocoshis
authors.forename: K
authors.initials: K
authors.lastname: Abu-Elmagd
authors.forename: S
authors.initials: S
authors.lastname: Todo
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D015994:Incidence; D007223:Infant; D007422:Intestines / Q000276:immunology / Q000473:pathology / Q000637:transplantation*; D008232:Lymphoproliferative Disorders / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D012189:Retrospective Studies; D016559:Tacrolimus / Q000009:adverse effects*; D013997:Time Factors
chemical_list: D016559:Tacrolimus